BNOX רווח עתידי Bionomics

לוגו תאגידי של חברת bionomics.com.au (BNOX)

High laboratory costs are creating financial pressure, as confirmed by the earnings forecast trend, where the indicator reached the level of . Bionomics Limited (BNOX) maintains stability through its Australian centers developing antidepressants. Growth potential is embedded in the upcoming results of PTSD drug trials, while current operating losses are already priced in by the market.

Bionomics Ltd. (BNOX): תחזית רווח נקי מ-04.07.2022 עד 16.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת Bionomics Ltd (BNOX)

- מחיר מניה וקונצנזוס הערכת שווי:
הערכת שווי פונדמנטלית של החברה:BNOX, Bionomics Limited
פריט של המותג Bionomics Ltd.

Bionomics Limited (BNOX) innovations in ion channel modulation for depression therapy are shaping long-term capitalization potential. This indicator synthesizes the market revenue consensus, adjusting the mathematical expectation via Sharpe and Sortino ratios to mitigate volatility. The metric transforms discrete reports into a continuous series of fundamental value. An analysis of the financial result forecast allows for the determination of the asset's fair valuation boundaries. Exceeding these limits risks overpayment and capital freezing.